N-decanoyl-2-amino-3-mercaptopropionic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-decanoyl-2-amino-3-mercaptopropionic acid
• 英文别名: N-decanoylcysteine；decanoyl-Cys；(2R)-2-(decanoylamino)-3-sulfanylpropanoic acid
• 化学式: C₁₃H₂₅NO₃S
• 分子量: 275.412
• InChiKey: CZJJQSUIALCKCZ-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  67.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  L-半胱氨酸 、 1H-1,2,3-benzotriazol-1-yl(n-nonyl)methanone 在 三乙胺 作用下， 以 水 、 乙腈 为溶剂， 反应 2.0h， 以70%的产率得到N-decanoyl-2-amino-3-mercaptopropionic acid
  参考文献：
  名称：

  新型抗菌自组装短脂肽

  摘要：

  脂肽是两亲性分子的一个特殊例子，可以自组装成功能结构，应用于纳米技术、催化或药物化学领域。在此，我们报告了 21 种短脂肽库，以及它们的超分子特征和针对革兰氏阴性（大肠杆菌）和革兰氏阳性（金黄色葡萄球菌）菌株的抗菌活性。这项研究表明，简单的脂肪氨基酸自组装成胶束或囊泡结构，同时掺入能够稳定氢键的二肽导致采用先进的纤维结构。自组装效应已被证明是实现抗菌活性的关键。

  DOI：

  10.1039/d1ob01227d

文献信息

• Novel peptide derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US04666886A1

  公开（公告）日：1987-05-19

  The invention relates to lipopeptides of the formula I, ##STR1## in which each of R.sub.a.sup.1 and R.sub.b.sup.1, independently of the other, represents an aliphatic or cycloaliphatic-aliphatic hydrocarbon radical having from 7 to 21 carbon atoms that is optionally substituted by oxygen functions, or one of the radicals R.sub.a.sup.1 --CO-- and R.sub.b.sup.1 --CO-- represents hydrogen and the other of the radicals R.sub.a.sup.1 --CO-- and R.sub.b.sup.1 --CO-- represents an acyl radical, wherein R.sub.a.sup.1 and R.sub.b.sup.1 have the meanings given above, R.sup.2 represents an aliphatic or cycloaliphatic-aliphatic hydrocarbon radical having from 1 to 21 carbon atoms that is optionally substituted by oxygen functions, n=0 or 1, As.degree. represents a radical of the formula --O--Kw--CO-- or --NH--Kw--CO-- wherein Kw represents an aliphatic hydrocarbon radical having a maximum of 12 carbon atoms, As.sup.1 represents a D- or L-.alpha.-amino acid, each of Z.sup.1 and Z.sup.2, independently of the other, represents hydroxy or the N-terminal radical of a D- or L-.alpha.-aminocarboxylic acid, of an amino-lower alkanesulphonic acid or of a peptide having a maximum of 6 amino acids from the group consisting of D- or L-.alpha.-aminocarboxylic acids and amino-lower alkanesulphonic acids, and Z.sup.3 represents hydrogen or --CO--Z.sup.4 wherein Z.sup.4 represents hydroxy or the N-terminal radical of a D- or L-.alpha.-amino acid, of an amino-lower alkanesulphonic acid or of a peptide having a maximum of 6 amino acids from the group consisting of D- or L-.alpha.-aminocarboxylic acids and amino-lower alkanesulphonic acids, and the amides and esters of such compounds that contain carboxy groups. The novel lipopeptides have an immunity-stimulating action.

  本发明涉及公式I的脂肽，其中R.sub.a.sup.1和R.sub.b.sup.1中的每一个，独立于另一个，代表具有7至21个碳原子的脂肪或环脂肪-脂肪烃基，可选地被氧功能取代，或者R.sub.a.sup.1 -CO-和R.sub.b.sup.1 -CO-中的一个代表氢，另一个代表酰基基团，其中R.sub.a.sup.1和R.sub.b.sup.1具有上述所给的含义，R.sup.2代表具有1至21个碳原子的脂肪或环脂肪-脂肪烃基，可选地被氧功能取代，n = 0或1，As.degree.代表公式-O-Kw-CO-或-NH-Kw-CO-的基团，其中Kw代表最多具有12个碳原子的脂肪烃基，As.sup.1代表D-或L-.alpha.-氨基酸，Z.sup.1和Z.sup.2中的每一个，独立于另一个，代表羟基或最多具有6个氨基酸的肽中D-或L-.alpha.-氨基酸和氨基低级烷磺酸的一个的N-末端基团，Z.sup.3代表氢或-CO-Z.sup.4，其中Z.sup.4代表羟基或最多具有6个氨基酸的肽中D-或L-.alpha.-氨基酸和氨基低级烷磺酸的一个的N-末端基团，以及含有羧基的这种化合物的酰胺和酯。这种新型脂肽具有免疫刺激作用。
• PHOTO-CURING MATERIAL MANUFACTURING METHOD, AND PHOTO-CURING MATERIAL AND ARTICLE
  申请人：Asahi Glass Company Limited

  公开号：EP2360195A1

  公开（公告）日：2011-08-24

  To provide a photocurable material which can form a cured product having a high transparency and a high refractive index, a process for producing the material easily, and an article having a high transparency and a high refractive index. The photocurable material is obtained by a production process comprising (i) a step of reacting a polymerizable component (A) comprised of at least one type of a compound (a) having a (meth)acryloyloxy group, and a compound (B) having a mercapto group and a carboxy group to obtain a surface modifier (C) which has the carboxy group derived from the compound (B) at a terminal, (ii) a step of modifying the surface of inorganic fine particles (D) with the surface modifier (C) to obtain surface-modified inorganic fine particles (E), and (iii) a step of obtaining a photocurable material which contains the surface-modified inorganic fine particles (E), a polymerizable component (F) comprised of at least one type of a compound (f) having a (meth)acryloyloxy group, and a photopolymerization initiator (G).

  提供一种可形成具有高透明度和高折射率的固化物的光固化材料、一种易于生产该材料的工艺以及一种具有高透明度和高折射率的制品。 这种光固化材料是通过以下生产工艺获得的： (i) 第一步：使由至少一种具有(甲基)丙烯酰氧基的化合物(a)和具有巯基和羧基的化合物(B)组成的可聚合组分(A)与表面改性剂(C)反应，表面改性剂(C)的末端具有来自化合物(B)的羧基、(ii) 用表面改性剂（C）改性无机微粒（D）的表面，以获得表面改性无机微粒 （E），以及 (iii) 获得光固化材料的步骤，该材料包含表面改性无机微粒（E）、由至少一种具有 （甲基）丙烯酰氧基的化合物（f）和光聚合引发剂（G）组成的可聚合组分（F）。
• Pharmaceutical formulations for the oral delivery of peptide or protein drugs
  申请人：Cyprumed GmbH

  公开号：EP3006045A1

  公开（公告）日：2016-04-13

  The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide or protein drugs with advantageously high bioavailability, safety and cost-effectiveness. In particular, the invention provides a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa for use as a medicament, wherein said peptide or protein drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex, and with a pharmaceutically acceptable reducing agent. The invention also provides a pharmaceutical composition comprising: a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex; and a pharmaceutically acceptable reducing agent.

  本发明涉及肽或蛋白质药物口服给药的改进药物制剂、用途和方法，具有生物利用度高、安全性好和成本效益高等优点。特别是，本发明提供了一种分子量等于或小于约 50 kDa 的多肽或蛋白质药物，可用作药物，其中所述多肽或蛋白质药物将与药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物以及药学上可接受的还原剂一起口服给药。本发明还提供了一种药物组合物，其中包括：分子量等于或小于约 50 kDa 的多肽或蛋白药物；药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物；以及药学上可接受的还原剂。
• Fast-acting plant-based medicinal compounds and nutritional supplements
  申请人：RECEPTOR HOLDINGS, INC.

  公开号：US10588974B2

  公开（公告）日：2020-03-17

  Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

  本文介绍了各种载体组合中的植物药用化合物或营养补充剂。载体可包括 N-酰化脂肪氨基酸、渗透促进剂和/或其他各种有益载体。植物性组合物/载体组合可带来用药益处。
• Pharmaceutical formulations for the oral delivery of peptide drugs
  申请人：Cyprumed GmbH

  公开号：US10905744B2

  公开（公告）日：2021-02-02

  The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide drugs with advantageously high bioavailability, safety and costeffectiveness. In particular, the invention provides a peptide drug having a molecular weight of equal to or less than 5 kDa for use as a medicament, wherein said peptide drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex, and with a pharmaceutically acceptable complexing agent. The invention also provides a pharmaceutical composition comprising: a peptide drug having a molecular weight of equal to or less than 5 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex; and a pharmaceutically acceptable complexing agent.

  本发明涉及肽类药物口服给药的改进药物制剂、用途和方法，具有生物利用度高、安全和成本效益高等优点。特别是，本发明提供了一种分子量等于或小于 5 kDa 的多肽药物，可用作药物，其中所述多肽药物将与药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物以及药学上可接受的络合剂一起口服给药。本发明还提供了一种药物组合物，其中包括：分子量等于或小于 5 kDa 的多肽药物；药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物；以及药学上可接受的络合剂。